Details of the Drug

General Information of Drug (ID: DMLB0EZ)

• Drug Name: Tamoxifen
• Synonyms: tamoxifen; 10540-29-1; trans-Tamoxifen; Crisafeno; Soltamox; Tamoxifene; Diemon; Tamoxifenum; Tamoxifeno; Tamizam; Istubol; Tamoxen; Citofen; Oncomox; Valodex; Retaxim; Tamoxifene [INN-French]; Tamoxifenum [INN-Latin]; Tamoxifeno [INN-Spanish]; Tamoxifen (Z); Tamoxifen and its salts; Tamoxifen [INN:BAN]; ICI-46474; ICI 47699; TRANS FORM OF TAMOXIFEN; CCRIS 3275; UNII-094ZI81Y45; HSDB 6782; CHEMBL83; EINECS 234-118-0; 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; Citofen; Nourytam; Novaldex; Tamone; Tamoxifeno;Tamoxifenum; Tomaxithen; Gen-Tamoxifen; Istubal (TN); Nolvadex (TN); Nolvadex-D; Novo-Tamoxifen; Pms-Tamoxifen; Tamoplex (TN); Tamoxifen (INN); Tamoxifen (TN); Trans-Tamoxifen; Valodex (TN); TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1)); Trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; (Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene; (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine; (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC); (Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE; (Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine; 1-p-beta-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene; 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene; 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; Tamoxifen (Hormonal therapy); [3H]tamoxifen

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1], [2]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 371.5
  Topological Polar Surface Area (xlogp); 7.1
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 0
  Hydrogen Bond Acceptor Count (hbondacc); 2
• ADMET Property:
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 40 mcg/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 5 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Clearance: The clearance of drug is 189 mL/min in postmenopausal women [5]
  Elimination: Animal studies have shown 75% of radiolabelled tamoxifen recovered in the feces, with negligible collection from urine [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 5 - 7 days [3]
  Metabolism: The drug is metabolized via the hydroxylated to -hydroxytamoxifen [7]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.18283 micromolar/kg/day [8]
  Vd: The volume of distribution (Vd) of drug is 50-60 L/kg [9]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.5 mg/mL [4]
• Chemical Identifiers:
  Formula: C26H29NO
  IUPAC Name: 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
  Canonical SMILES: CC/C(=C(\\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3
  InChI: InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
  InChIKey: NKANXQFJJICGDU-QPLCGJKRSA-N
• Cross-matching ID:
  PubChem CID: 2733526
  ChEBI ID: CHEBI:41774
  CAS Number: 10540-29-1
  DrugBank ID: DB00675
  TTD ID: D07KSG
  VARIDT ID: DR00193
  INTEDE ID: DR1529
  ACDINA ID: D00650

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Antagonist	[10], [11]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 7 (ABCC10)	DTPS120	MRP7_HUMAN	Substrate	[12]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[13]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[14]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[15]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[16]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[17]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[18]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[19]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[20]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[21]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[16]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[22]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[23]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[24]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[25]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[26]
Sulfotransferase 2A1 (SULT2A1) Main DME	DE0P6LK	ST2A1_HUMAN	Substrate	[]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[27]
UDP-glucuronosyltransferase 1A10 (UGT1A10)	DEL5N6Y	UD110_HUMAN	Substrate	[28]
Thiopurine methyltransferase (TPMT)	DEFQ8VO	TPMT_HUMAN	Substrate	[29]

Molecular Expression Atlas of This Drug

• The Studied Disease: Breast cancer
• ICD Disease Classification: 2C60-2C65

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.23E-01	-8.20E-02	-3.22E-01
Multidrug resistance-associated protein 7 (ABCC10)	DTP	MRP7	6.29E-01	6.44E-02	9.67E-02
Breast cancer resistance protein (ABCG2)	DTP	BCRP	9.93E-01	-1.09E-01	-5.77E-01
Sulfotransferase 1A1 (SULT1A1)	DME	SULT1A1	6.22E-02	1.64E-01	5.58E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	7.69E-01	1.91E-02	5.45E-02
Cytochrome P450 2E1 (CYP2E1)	DME	CYP2E1	7.75E-01	-1.76E-01	-6.23E-01
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	3.97E-02	-1.72E-01	-9.29E-01
Cytochrome P450 2A6 (CYP2A6)	DME	CYP2A6	7.56E-01	-6.70E-02	-3.47E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	9.96E-01	-7.53E-02	-5.68E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	5.82E-01	-6.00E-02	-2.69E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	3.44E-01	-1.85E-01	-5.25E-01
Thiopurine methyltransferase (TPMT)	DME	TPMT	8.48E-01	-1.76E-01	-5.49E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.95E-01	-7.47E-02	-2.45E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	5.01E-01	-1.01E-02	-6.05E-02
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	9.09E-01	-9.26E-02	-3.68E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.85E-01	2.24E-02	7.33E-02

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Tamoxifen

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Eribulin.	Breast cancer [2C60-2C6Y]	[174]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[175]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Lapatinib.	Breast cancer [2C60-2C6Y]	[174]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Tamoxifen caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[176]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Tamoxifen caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[177]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Bosutinib.	Breast cancer [2C60-2C6Y]	[178]

Coadministration of a Drug Treating the Disease Different from Tamoxifen (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Tamoxifen and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[179]
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Tamoxifen caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[180]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Ivosidenib.	Acute myeloid leukaemia [2A60]	[181]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Midostaurin.	Acute myeloid leukaemia [2A60]	[174]
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[182]
Daunorubicin	DMQUSBT	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Daunorubicin.	Acute myeloid leukaemia [2A60]	[182]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Tamoxifen caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[183]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Gilteritinib.	Acute myeloid leukaemia [2A60]	[184]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Oliceridine.	Acute pain [MG31]	[174]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Rivastigmine.	Alzheimer disease [8A20]	[174]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Donepezil.	Alzheimer disease [8A20]	[174]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Tamoxifen and Metronidazole.	Amoebiasis [1A36]	[179]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Ivabradine.	Angina pectoris [BA40]	[178]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Bepridil.	Angina pectoris [BA40]	[174]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Dronedarone.	Angina pectoris [BA40]	[174]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[185]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Tamoxifen caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[183]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Posaconazole.	Aspergillosis [1F20]	[174]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Levalbuterol.	Asthma [CA23]	[186]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Terbutaline.	Asthma [CA23]	[187]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Pirbuterol.	Asthma [CA23]	[187]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Salbutamol.	Asthma [CA23]	[186]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Formoterol.	Asthma [CA23]	[187]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[178]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[174]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[188]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Tamoxifen caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[189]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[174]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Tamoxifen and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[174]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[188]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[188]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[188]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[188]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[174]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Telithromycin.	Bacterial infection [1A00-1C4Z]	[174]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Tamoxifen and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[190]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[191]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[187]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[186]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[187]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[187]
Arformoterol	DMYM974	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[187]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Tamoxifen caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[183]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Tamoxifen due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[179]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Isoproterenol.	Conduction disorder [BC63]	[186]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Halothane.	Corneal disease [9A76-9A78]	[174]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Propofol.	Corneal disease [9A76-9A78]	[192]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Probucol.	Coronary atherosclerosis [BA80]	[174]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Mifepristone.	Cushing syndrome [5A70]	[174]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Pasireotide.	Cushing syndrome [5A70]	[174]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Osilodrostat.	Cushing syndrome [5A70]	[178]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Tamoxifen caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[193]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Tamoxifen caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[194]
Sertraline	DM0FB1J	Major	Decreased metabolism of Tamoxifen caused by Sertraline mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[195]
Trimipramine	DM1SC8M	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Trimipramine.	Depression [6A70-6A7Z]	[174]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Tamoxifen caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[196]
Paroxetine	DM5PVQE	Major	Decreased metabolism of Tamoxifen caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[195]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Clomipramine.	Depression [6A70-6A7Z]	[174]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Doxepin.	Depression [6A70-6A7Z]	[174]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Maprotiline.	Depression [6A70-6A7Z]	[174]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[174]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Tamoxifen and Deutetrabenazine.	Dystonic disorder [8A02]	[197]
Ingrezza	DMVPLNC	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Ingrezza.	Dystonic disorder [8A02]	[198]
Primidone	DM0WX6I	Moderate	Increased metabolism of Tamoxifen caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[183]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Tamoxifen caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[183]
Cenobamate	DMGOVHA	Moderate	Increased metabolism of Tamoxifen caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[183]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Tamoxifen caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[183]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Tamoxifen caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[183]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Tamoxifen and Cannabidiol.	Epileptic encephalopathy [8A62]	[178]
Diphenhydramine	DMKQTBA	Major	Decreased metabolism of Tamoxifen caused by Diphenhydramine mediated inhibition of CYP450 enzyme.	Episodic vestibular syndrome [AB31]	[195]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Solifenacin.	Functional bladder disorder [GC50]	[174]
Mirabegron	DMS1GYT	Major	Decreased metabolism of Tamoxifen caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[195]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Tamoxifen caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[199]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Pentamidine.	Fungal infection [1F29-1F2F]	[174]
Terbinafine	DMI6HUW	Major	Decreased metabolism of Tamoxifen caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[195]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Ketoconazole.	Fungal infection [1F29-1F2F]	[174]
Ripretinib	DM958QB	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Ripretinib.	Gastrointestinal stromal tumour [2B5B]	[179]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[174]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Tamoxifen caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[183]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Tamoxifen caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[183]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Tamoxifen caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[183]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Tamoxifen and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[200]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[201]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Tamoxifen caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[202]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[203]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[174]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Tamoxifen caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[204]
Maraviroc	DMTL94F	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[205]
Fenofibrate	DMFKXDY	Moderate	Decreased metabolism of Tamoxifen caused by Fenofibrate mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[179]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Tamoxifen and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[206]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Tamoxifen and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[174]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Tamoxifen and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[207]
Cinacalcet	DMCX0K3	Major	Decreased metabolism of Tamoxifen caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[195]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Tamoxifen caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[208]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[209]
Givosiran	DM5PFIJ	Major	Decreased metabolism of Tamoxifen caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[195]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Tamoxifen caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[210]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Tamoxifen caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[183]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[178]
Naloxegol	DML0B41	Minor	Decreased clearance of Tamoxifen due to the transporter inhibition by Naloxegol.	Large intestine motility disorder [DB32]	[211]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Tamoxifen caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[178]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Crizotinib.	Lung cancer [2C25]	[212]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Tamoxifen caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[213]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Ceritinib.	Lung cancer [2C25]	[174]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Tamoxifen caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[183]
Dacomitinib	DMOH8VY	Major	Decreased metabolism of Tamoxifen caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[195]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Osimertinib.	Lung cancer [2C25]	[214]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Selpercatinib.	Lung cancer [2C25]	[178]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Lumefantrine.	Malaria [1F40-1F45]	[179]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Hydroxychloroquine.	Malaria [1F40-1F45]	[215]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Primaquine.	Malaria [1F40-1F45]	[174]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[178]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Tamoxifen and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[216]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Tamoxifen and Idelalisib.	Mature B-cell leukaemia [2A82]	[217]
GDC-0199	DMH0QKA	Major	Decreased clearance of Tamoxifen due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[179]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Tamoxifen caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[218]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[219]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[179]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Vemurafenib.	Melanoma [2C30]	[174]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and LGX818.	Melanoma [2C30]	[220]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Tamoxifen caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[183]
Ubrogepant	DM749I3	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Ubrogepant.	Migraine [8A80]	[221]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Tamoxifen caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[222]
Carfilzomib	DM48K0X	Major	Additive thrombogenic effects by the combination of Tamoxifen and Carfilzomib.	Multiple myeloma [2A83]	[179]
Panobinostat	DM58WKG	Major	Decreased metabolism of Tamoxifen caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[195]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Siponimod.	Multiple sclerosis [8A40]	[179]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Fingolimod.	Multiple sclerosis [8A40]	[174]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Ozanimod.	Multiple sclerosis [8A40]	[223]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Romidepsin.	Mycosis fungoides [2B01]	[174]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Tamoxifen caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[195]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Nilotinib.	Myeloproliferative neoplasm [2A20]	[174]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Dasatinib.	Myeloproliferative neoplasm [2A20]	[224]
Prasugrel	DM7MT6E	Minor	Decreased metabolism of Tamoxifen caused by Prasugrel mediated inhibition of CYP450 enzyme.	Myocardial infarction [BA41-BA43]	[178]
Modafinil	DMYILBE	Moderate	Increased metabolism of Tamoxifen caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[183]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Promethazine.	Nausea/vomiting [MD90]	[174]
Rolapitant	DM8XP26	Major	Decreased metabolism of Tamoxifen caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[195]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Granisetron.	Nausea/vomiting [MD90]	[174]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Dolasetron.	Nausea/vomiting [MD90]	[174]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Ondansetron.	Nausea/vomiting [MD90]	[174]
Bupropion	DM5PCS7	Major	Decreased metabolism of Tamoxifen caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[195]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Entrectinib.	Non-small cell lung cancer [2C25]	[179]
Lorcaserin	DMG6OYJ	Major	Decreased metabolism of Tamoxifen caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[195]
Dexfenfluramine	DMJ7YDS	Major	Decreased metabolism of Tamoxifen caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[195]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Levomethadyl Acetate.	Opioid use disorder [6C43]	[178]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Lofexidine.	Opioid use disorder [6C43]	[174]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Tamoxifen caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[179]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Rucaparib.	Ovarian cancer [2C73]	[174]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Buprenorphine.	Pain [MG30-MG3Z]	[174]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Triclabendazole.	Parasitic worm infestation [1F90]	[174]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Pimavanserin.	Parkinsonism [8A00]	[225]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Apomorphine.	Parkinsonism [8A00]	[174]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Tamoxifen caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[226]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Famotidine.	Peptic ulcer [DA61]	[179]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[227]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Lefamulin.	Pneumonia [CA40]	[228]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Tamoxifen caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[229]
Ritodrine	DM4V6RL	Moderate	Increased risk of ventricular arrhythmias by the combination of Tamoxifen and Ritodrine.	Preterm labour/delivery [JB00]	[187]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Degarelix.	Prostate cancer [2C82]	[178]
ABIRATERONE	DM8V75C	Major	Decreased metabolism of Tamoxifen caused by ABIRATERONE mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[195]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Tamoxifen caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[183]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Relugolix.	Prostate cancer [2C82]	[178]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Bicalutamide.	Prostate cancer [2C82]	[178]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Levomepromazine.	Psychotic disorder [6A20-6A25]	[174]
Riociguat	DMXBLMP	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Riociguat.	Pulmonary hypertension [BB01]	[179]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Tamoxifen and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[230]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[231]
Dexamethasone	DMMWZET	Moderate	Increased metabolism of Tamoxifen caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[183]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Quetiapine.	Schizophrenia [6A20]	[174]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Mesoridazine.	Schizophrenia [6A20]	[174]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Thioridazine.	Schizophrenia [6A20]	[174]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Iloperidone.	Schizophrenia [6A20]	[174]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Paliperidone.	Schizophrenia [6A20]	[174]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Perphenazine.	Schizophrenia [6A20]	[174]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Trifluoperazine.	Schizophrenia [6A20]	[174]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Amisulpride.	Schizophrenia [6A20]	[232]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Asenapine.	Schizophrenia [6A20]	[174]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Pimozide.	Schizophrenia [6A20]	[178]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Vardenafil.	Sexual dysfunction [HA00-HA01]	[174]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Tamoxifen caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[178]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Tamoxifen and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[178]
Armodafinil	DMGB035	Moderate	Increased metabolism of Tamoxifen caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[183]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[174]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[178]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[174]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Tamoxifen and Naltrexone.	Substance abuse [6C40]	[233]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[234]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Tamoxifen due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[235]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Tamoxifen caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[178]
Clopidogrel	DMOL54H	Minor	Decreased metabolism of Tamoxifen caused by Clopidogrel mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[236]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Lenvatinib.	Thyroid cancer [2D10]	[174]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Cabozantinib.	Thyroid cancer [2D10]	[178]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Papaverine.	Tonus and reflex abnormality [MB47]	[237]
Tizanidine	DMR2IQ4	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Tizanidine.	Tonus and reflex abnormality [MB47]	[174]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Tamoxifen and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[230]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Tacrolimus.	Transplant rejection [NE84]	[174]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Tamoxifen caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[183]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[238]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Procainamide.	Ventricular tachyarrhythmia [BC71]	[174]
Propafenone	DMPIBJK	Major	Decreased metabolism of Tamoxifen caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[195]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Tamoxifen and Flecainide.	Ventricular tachyarrhythmia [BC71]	[174]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Tamoxifen and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[174]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Anethole	E00440	637563	Flavoring agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Ethanol	E00023	702	Antimicrobial preservative; Penetration agent; Solvent
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
Sorbitan tristearate	E00516	17800859	Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Tamoxifen 10 mg tablet	10 mg	Oral Tablet	Oral
Tamoxifen 20 mg tablet	20 mg	Oral Tablet	Oral
Tamoxifen Citrate eq 10mg base tablet	eq 10mg base	Tablet	Oral
Tamoxifen Citrate eq 20mg base/10ml solution	eq 20mg base/10ml	Solution	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1016).
• [2] Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer. 2008 Nov 1;113(9):2385-97.
• [3] FDA Approved Drug Products: Tamoxifen Oral Tablets
• [4] BDDCS applied to over 900 drugs
• [5] Lien EA, Anker G, Lonning PE, Solheim E, Ueland PM: Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 1990 Sep 15;50(18):5851-7.
• [6] Fromson JM, Pearson S, Bramah S: The metabolism of tamoxifen (I.C.I. 46,474). I. In laboratory animals. Xenobiotica. 1973 Nov;3(11):693-709. doi: 10.3109/00498257309151594.
• [7] Brocks DR: Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999 May-Aug;2(2):39-46.
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM: Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 1989 Apr 15;49(8):2175-83.
• [10] Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
• [11] Chemoprevention for high-risk women: tamoxifen and beyond. Breast J. 2001 Sep-Oct;7(5):311-20.
• [12] Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
• [13] The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
• [14] Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
• [15] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [16] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [17] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [18] Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
• [19] Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
• [20] Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
• [21] Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
• [22] Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
• [23] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [24] Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
• [25] Drug Interactions Flockhart Table
• [26] Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
• [27] Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
• [28] Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
• [29] Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
• [30] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [31] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [32] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [33] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [34] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [35] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [36] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [37] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [38] Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
• [39] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [40] Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
• [41] Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
• [42] PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
• [43] The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
• [44] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [45] Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
• [46] Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
• [47] Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
• [48] Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
• [49] Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
• [50] UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
• [51] Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
• [52] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [53] Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
• [54] Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
• [55] Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
• [56] Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
• [57] Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
• [58] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [59] Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
• [60] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [61] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [62] CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
• [63] Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
• [64] Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
• [65] Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
• [66] Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
• [67] A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
• [68] Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
• [69] Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
• [70] Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
• [71] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [72] Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
• [73] Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
• [74] Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
• [75] Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
• [76] Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
• [77] Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
• [78] Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
• [79] Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
• [80] Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
• [81] The 2.7 A resolution structure of the glycopeptide sulfotransferase Teg14. Acta Crystallogr D Biol Crystallogr. 2010 Dec;66(Pt 12):1278-86.
• [82] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [83] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [84] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [85] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [86] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [87] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [88] Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
• [89] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [90] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [91] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [92] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [93] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [94] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [95] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [96] 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
• [97] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [98] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [99] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [100] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [101] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [102] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [103] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
• [104] Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
• [105] Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
• [106] Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
• [107] The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010 Apr;24(4):715-20.
• [108] Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8.
• [109] Ascorbic acid inhibits spinal meningeal catechol-o-methyl transferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology. 1997 Feb;86(2):405-9.
• [110] Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
• [111] Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7.
• [112] Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
• [113] Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
• [114] Nodular regenerative liver hyperplasia as a complication of azathioprine-containing immunosuppressive treatment for Crohn's disease. Immunopharmacol Immunotoxicol. 2011 Jun;33(2):398-402.
• [115] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [116] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [117] Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
• [118] Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
• [119] Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
• [120] Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
• [121] Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
• [122] New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
• [123] A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
• [124] A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
• [125] In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol. 1996;50(3):209-15.
• [126] Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
• [127] Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
• [128] Drugs that may have potential CYP2B6 interactions.
• [129] Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
• [130] Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
• [131] PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
• [132] Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
• [133] High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
• [134] CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
• [135] Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
• [136] Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
• [137] Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
• [138] Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
• [139] PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
• [140] Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
• [141] Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
• [142] Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
• [143] Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
• [144] UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
• [145] [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
• [146] S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
• [147] Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
• [148] In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9.
• [149] UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132.
• [150] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [151] MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
• [152] Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
• [153] Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
• [154] Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
• [155] Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
• [156] Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
• [157] Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
• [158] Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
• [159] The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
• [160] Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
• [161] Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
• [162] Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
• [163] Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
• [164] Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
• [165] Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
• [166] Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. J Infect Dis. 2011 Jul 1;204(1):145-53.
• [167] Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
• [168] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [169] 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
• [170] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
• [171] Clinical pipeline report, company report or official report of Shionogi (2011).
• [172] Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.
• [173] Short-term effects of environmentally relevant concentrations of EDC mixtures on Mytilus galloprovincialis digestive gland. Aquat Toxicol. 2008 May 30;87(4):272-9.
• [174] Canadian Pharmacists Association.
• [175] Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [176] Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
• [177] Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
• [178] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [179] Cerner Multum, Inc. "Australian Product Information.".
• [180] Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
• [181] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [182] Multum Information Services, Inc. Expert Review Panel.
• [183] Biochem Pharmacol "Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes." Biochem Pharmacol 53 (1997): 171-8. [PMID: 9037249]
• [184] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [185] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [186] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [187] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [188] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [189] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77. [PMID: 11103749]
• [190] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [191] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [192] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [193] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [194] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [195] Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
• [196] Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
• [197] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [198] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [199] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
• [200] Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
• [201] Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
• [202] Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
• [203] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [204] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [205] Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [206] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [207] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [208] Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
• [209] Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [210] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [211] Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [212] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [213] Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [214] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [215] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [216] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [217] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [218] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [219] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [220] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [221] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [222] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [223] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [224] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [225] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [226] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [227] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [228] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [229] Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
• [230] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [231] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [232] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [233] Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
• [234] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [235] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
• [236] Product Information. Plavix (clopidogrel). Bristol-Myers Squibb, Princeton, NJ.
• [237] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
• [238] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]